Frédéric Collet

Frédéric Collet was appointed to the board of Advanced Accelerator Applications (AAA) in January 2018, following the completion of a tender offer for the company by Novartis. He has served as the President of Novartis France since 2017, and as Chief Executive of Novartis Oncology in France since 2015. As of 2017, he also heads the Novartis Group Executive Committee, which brings together Novartis Pharmaceuticals and Oncology, Sandoz and Alcon. Frédéric currently sits on the board of the French Pharmaceutical Industry Trade Association (LEEM), is President of the LEEM Cancer Group, and he leads the European Family. From 2009 to 2015, Frédéric was President of Sandoz France. He also served as Vice President of the French Generics and Bio-similars Professional Association (GEMME). Before this, he was General Manager of the Ciba Vision division from 2005 to 2009. Prior to joining Ciba Vision, Frédéric spent 12 years in various managerial roles within the cosmetics division of the Henkel Group. Frédéric graduated from the Institut d’´Etudes Politiques in Paris and holds a Master’s degree in Economic Science from the University of Paris II.